CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DFGFR1OP2::FGFR1FusionPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaPonatinibGozgit et al., 2011
DKITA502_Y503insAYPredictiveSupportsSensitivity/ResponseCancerSunitinibGarner et al., 2014
DKIAA1549::BRAFFusionPredictiveSupportsResistanceChildhood Pilocytic AstrocytomaVemurafenib,SorafenibSelt et al., 2017
CPDE4DIP::NTRK1FusionPredictiveSupportsSensitivity/ResponseSarcomaLarotrectinibDuBois et al., 2018
BCDKN2ALossPredictiveDoes Not SupportResistanceLung Non-small Cell CarcinomaPalbociclibEugene R Ahn, 2019, ASCO Annual Meeting, Abstract 9041
BSTAG2MUTATIONPrognosticDoes Not SupportPoor OutcomeAcute Myeloid LeukemiaThol et al., 2014
CKITD816VPredictiveSupportsResistanceCancerImatinib,DasatinibVita et al., 2014
CTP53R175H OR TP53 H193RPredictiveSupportsSensitivity/ResponseSarcomaPazopanib,VorinostatFu et al., 2015
BEGFRExon 20 InsertionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
DBRAFA728VFunctionalSupportsGain of FunctionWan et al., 2004
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibMahjoubi et al., 2016
DBCR::ABL1Fusion AND ABL1 T315VPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 V299LPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 T315APredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 M351TPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 H396PPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E279KPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E292LPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 F317RPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 L248R AND ABL1 F359IPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 L248RPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E255K AND ABL1 V299LPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinib,PonatinibPemovska et al., 2015
DCDK4EXPRESSIONPredictiveSupportsSensitivity/ResponseChildhood B-cell Acute Lymphoblastic LeukemiaDexamethasone,RibociclibBortolozzi et al., 2018
DCDK6OverexpressionPredictiveSupportsSensitivity/ResponseGlioblastoma Proneural SubtypePalbociclibLi et al., 2017
DCDK6EXPRESSIONPredictiveSupportsSensitivity/ResponseChildhood B-cell Acute Lymphoblastic LeukemiaRibociclib,DexamethasoneBortolozzi et al., 2018
CNT5C2R367QPredictiveSupportsResistanceChildhood Acute Lymphocytic LeukemiaThioguanine,MercaptopurineMeyer et al., 2013
CNT5C2R238WPrognosticSupportsPoor OutcomeChildhood Acute Lymphocytic LeukemiaMeyer et al., 2013
CNT5C2S445FPrognosticSupportsPoor OutcomeChildhood Acute Lymphocytic LeukemiaMeyer et al., 2013
DPRPS1N144SPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaCytarabineLi et al., 2015
DPRPS1L191FPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaCytarabineLi et al., 2015
DIL6OverexpressionPredictiveSupportsResistanceRhabdomyosarcomaBazedoxifeneXiao et al., 2017
COFD1::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeYano et al., 2015
CNF2c.1396C>TPredisposingSupportsPredispositionAdult Spinal Cord EpendymomaPlotkin et al., 2011
CBCR::ABL1Fusion AND ABL1 F486SPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CBCR::ABL1Fusion AND ABL1 E459KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CABL1P-Loop MutationPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
COFD1::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeImamura et al., 2016
DFLT3D835YPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
BCCND1OverexpressionPrognosticSupportsPoor OutcomeChildhood B-cell Acute Lymphoblastic LeukemiaBortolozzi et al., 2018
DPIK3CAK111NPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab,Dactolisib,LapatinibEichhorn et al., 2008
CBCL2G101VPredictiveSupportsResistanceChronic Lymphocytic Leukemia/small Lymphocytic LymphomaVenetoclaxLucas et al., 2020
BMYOD1L122RPrognosticSupportsPoor OutcomeSpindle Cell RhabdomyosarcomaRekhi et al., 2016
DPIK3CAAmplificationPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerLapatinib,DactolisibEichhorn et al., 2008
DPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabEichhorn et al., 2008
DPTENLoss AND PIK3CA K111NPredictiveSupportsResistanceHer2-receptor Positive Breast CancerDactolisibEichhorn et al., 2008
DPTENLossPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerDactolisib,LapatinibEichhorn et al., 2008
DPTENLossPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerDactolisib,TrastuzumabEichhorn et al., 2008
CFLT3D835PrognosticSupportsPoor OutcomeMyelodysplastic SyndromeShih et al., 2004
Page 85 of 96
PreviousNext